Campbell & CO Investment Adviser LLC Takes $618,000 Position in Xeris Biopharma Holdings, Inc. $XERS

Campbell & CO Investment Adviser LLC acquired a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 132,382 shares of the company’s stock, valued at approximately $618,000. Campbell & CO Investment Adviser LLC owned 0.08% of Xeris Biopharma as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in XERS. Xponance Inc. bought a new position in Xeris Biopharma during the first quarter worth about $57,000. FORA Capital LLC acquired a new stake in shares of Xeris Biopharma in the 1st quarter valued at approximately $60,000. R Squared Ltd boosted its stake in Xeris Biopharma by 27.7% during the 1st quarter. R Squared Ltd now owns 15,730 shares of the company’s stock worth $86,000 after acquiring an additional 3,410 shares during the last quarter. Landscape Capital Management L.L.C. bought a new position in Xeris Biopharma during the 1st quarter worth approximately $86,000. Finally, Aigen Investment Management LP acquired a new position in Xeris Biopharma during the first quarter valued at approximately $92,000. Institutional investors own 42.75% of the company’s stock.

Insider Transactions at Xeris Biopharma

In related news, Director Marla Persky sold 15,500 shares of the stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $7.72, for a total transaction of $119,660.00. Following the completion of the transaction, the director owned 142,000 shares in the company, valued at approximately $1,096,240. This represents a 9.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey W. Sherman sold 42,232 shares of Xeris Biopharma stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $7.92, for a total transaction of $334,477.44. Following the completion of the sale, the director owned 219,188 shares in the company, valued at $1,735,968.96. The trade was a 16.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 74,399 shares of company stock valued at $577,473 in the last ninety days. 6.47% of the stock is currently owned by corporate insiders.

Xeris Biopharma Price Performance

XERS opened at $7.18 on Friday. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -71.79 and a beta of 0.21. The business’s 50-day moving average price is $8.35 and its two-hundred day moving average price is $6.48. Xeris Biopharma Holdings, Inc. has a 1 year low of $2.82 and a 1 year high of $10.08.

Wall Street Analyst Weigh In

XERS has been the topic of several analyst reports. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 8th. Zacks Research downgraded Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 30th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Leerink Partners increased their price target on Xeris Biopharma from $7.00 to $9.00 and gave the stock an “outperform” rating in a report on Tuesday, August 19th. Finally, Piper Sandler raised their price target on Xeris Biopharma from $6.00 to $8.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.58.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.